Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Current Assets (2017 - 2025)

Fennec Pharmaceuticals (FENC) has disclosed Current Assets for 9 consecutive years, with $46.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Current Assets fell 20.53% year-over-year to $46.1 million, compared with a TTM value of $46.1 million through Sep 2025, down 20.53%, and an annual FY2024 reading of $44.1 million, up 64.29% over the prior year.
  • Current Assets was $46.1 million for Q3 2025 at Fennec Pharmaceuticals, up from $40.8 million in the prior quarter.
  • Across five years, Current Assets topped out at $68.2 million in Q1 2024 and bottomed at $15.6 million in Q2 2022.
  • Average Current Assets over 5 years is $34.6 million, with a median of $27.9 million recorded in 2021.
  • The sharpest move saw Current Assets tumbled 44.6% in 2022, then surged 221.62% in 2024.
  • Year by year, Current Assets stood at $26.0 million in 2021, then grew by 2.88% to $26.7 million in 2022, then grew by 0.49% to $26.9 million in 2023, then skyrocketed by 64.29% to $44.1 million in 2024, then grew by 4.4% to $46.1 million in 2025.
  • Business Quant data shows Current Assets for FENC at $46.1 million in Q3 2025, $40.8 million in Q2 2025, and $43.0 million in Q1 2025.